acebutolol has been researched along with Remission, Spontaneous in 1 studies
Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.
acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.
Remission, Spontaneous: A spontaneous diminution or abatement of a disease over time, without formal treatment.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
1 trial available for acebutolol and Remission, Spontaneous
| Article | Year |
|---|---|
A new beta-adrenergic blocking drug in hypertension. A report from the General Practitioner Research Group.
Topics: Acebutolol; Bendroflumethiazide; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans | 1976 |